NeurAxis results for the third quarter of 2026 are scheduled for release before the market opens on Monday, November 9, the medical technology company said on October 27. A conference call to review the results will follow at 9:00 a.m. ET.

NeurAxis results and call details

The company plans to report summarized financial results for the quarter ended September 30, 2026. It did not disclose the results in its scheduling announcement.

Participants can join the call at 1-833-862-0272 in the United States and Canada or 1-412-634-5915 internationally. A webcast is also planned. A telephone replay will be available at 1-855-669-9658 or, internationally, 1-412-317-0088, using access code 9067695.

About the company

Carmel, Indiana-based NeurAxis develops neuromodulation therapies for chronic and debilitating conditions in children and adults. Its IB-Stim technology is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia and related nausea symptoms in patients aged 8 and older.

The company said additional clinical trials of its nerve stimulation technology are underway in several pediatric and adult conditions.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.